The development of longer-acting and more potent NUSH receptor agonists, like semaglutide, has helped clarify the link between aberrant glucose metabolism and a range of diseases. Learn how to embrace the multi-indicatio...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Applied Clinical Trials interview series on study startup
Brian Mallon, EVP Site and Patient Solutions, recently joined Applied Clinical Trials for a five part interview series examining the forces reshaping study startup and the practical strategies sponsors and CROs can use to restore predictability, strengthen site relationships and accelerate activation.
-
Interview series: Part 1 of 5 - Rethinking site activation to cut startup timelines
How contract standardisation, proactive budget alignment, and AI-enabled negotiation tools can reduce site activation delays and turn agreements into strategic accelerators.
-
Closing communication gaps during study startup
Why persistent communication breakdowns between sponsors, CROs, and sites undermine startup efficiency—and how bidirectional, site-informed engagement models can improve collaboration and momentum.
-
Applying AI to reduce administrative burden without losing the human touch
How practical AI applications can streamline contracts and startup workflows while preserving the central role of investigators, site staff, and patient relationships.
-
Why startup timelines are worsening – and how to reduce the trend
The operational pressures driving longer activation timelines, from protocol complexity to site competition, and how earlier, more flexible site engagement can restore momentum.
-
Centering site experience to accelerate site activation
How sponsor and CRO practices that prioritise site needs, clarity, and partnership can strengthen trust, sustain momentum, and speed activation.
-
Examining the growing delays in clinical trial start-up
Brian Mallon discusses the increasing timeframe from site selection to full activation, including the issues contributing to the delay and measures to address them.
-
Pharma communications resilience: Navigating regulatory policy shifts with strategic precision
Regulatory change often brings unexpected challenges to an already complex environment. Product labelling is no exception. Yet, with the right foundation, organisations can transform uncertainty into opportunity. A well-balanced mix of skilled personnel, timely intelligence and agile processes equips organisations to stay ahead of regulatory shifts.
-
Enabling Innovation: How China-based biotechs are shaping global drug development
Yao Zhong, ICON China Mainland and Hong Kong, is sharing some of the findings from the 2025 China biotech sector survey report. Read more on how a strategic partnership fuels global ambition.
-
Next-generation modalities, precision trials, and AI-driven breakthroughs in oncology
The panelists discussed promising scientific and strategic pathways in oncology, including next-generation therapeutic modalities, precision trial strategies, AI applications with demonstrated and measurable impact, regulatory and market readiness, and collaborative models for accelerating early-phase oncology programs.
